Behçet's syndrome: A critical digest of the 2012-1213 literature

Clinical and Experimental Rheumatology

Volumn 31, Issue SUPPL.77, 2013, Pages

  Hatemi Prof , Gulen ^a   Seyahi Prof , Emire ^a   Fresko Prof , Izzet ^a   Hamuryudan, Vedat ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Beh et's syndrome; Clinical manifestations; Epidemiology; Genetics; Pathogenesis; Treatment

Indexed keywords

ADALIMUMAB; ALEMTUZUMAB; BIOLOGICAL PRODUCT; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR3; CORTICOSTEROID; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 17; PLACEBO; SECUKINUMAB; STAT4 PROTEIN; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; USTEKINUMAB;

AUTOIMMUNE DISEASE; BEHCET DISEASE; CCR1 GENE; CCR2 GENE; CCR3 GENE; CHRONIC DISEASE; CLINICAL FEATURE; COGNITIVE DEFECT; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERAP 1 GENE; EXECUTIVE FUNCTION; EYE DISEASE; GASTROINTESTINAL DISEASE; GENE; GENETIC ASSOCIATION; HEART; HUMAN; KLRC4 GENE; MULTIPLE SCLEROSIS; ONSET AGE; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; RELAPSE; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; STAT4 GENE; SYSTEMIC LUPUS ERYTHEMATOSUS; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY;

ANIMALS; BEHCET SYNDROME; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PHENOTYPE; PROGNOSIS; RISK FACTORS;

EID: 84884967131     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Review

References (82)

1. SHAHRAM F, JAMSHIDI AR, HIRBOD-MOBARAKEH A, HABIBI G, MARDANI A, GHAEMI M: Scientometric analysis and mapping of scientific articles on Behçet's disease. Int J Rheum Dis 2013; 16: 185-92.
2. ZHANG Z, HE F, SHI Y: Behçet's disease seen in China: analysis of 334 cases. Rheumatol Int 2013; 33: 645-8.
3. SINGAL A, CHHABRA N, PANDHI D, ROHATGI J: Behçet's disease in India: adermatological perspective. Indian J Dermatol Venereol Leprol 2013; 79:199-204.
4. YU KH, SEE LC, KUO CF, CHOU IJ, CHOU MJ: Prevalence and incidence in patients with autoimmune rheumatic diseases: a nationwide population-based study in Taiwan. Arthritis Care Res (Hoboken) 2013; 65: 244-50.
5. KANEKO F, NAKAMURA K, SATO M, TOJO M, ZHENG X, ZHANG JZ: Epidemiology of Behçet's disease in Asian countries and Japan. Adv Exp Med Biol 2003; 528: 25-9.
6. OLIVIERI I, LECCESE P, PADULA A et al.: High prevalence of Behçet's disease in southern Italy. Clin Exp Rheumatol 2013 Apr 2 (Epub ahead of print).
7. SALVARANI C, PIPITONE N, CATANOSO MG et al.: Epidemiology and clinical course of Behçet's disease in the Reggio Emilia area of Northern Italy: a seventeen-year populationbased study. Arthritis Rheum 2007; 57: 171-8.
8. MOHAMMAD A, MANDL T, STURFELT G, SEGELMARK M: Incidence, prevalence and clinical characteristics of Behçet's disease in southern Sweden. Rheumatology (Oxford) 2013; 52: 304-10.
9. EK L, HEDFORS E: Behçet's disease: a review and a report of 12 cases from Sweden. Acta Derm Venerol 1993; 73: 251-4.
10. GYLDENLøVE M, TVEDE N, LARSEN JL, JACOBSEN S, THYSSEN JP: Low prevalence ofpositive skin pathergy testing in Danish patients with Behçet's disease. J EurAcad Dermatol Venereol 2013 May 16 (Epub ahead of print).
11. NASHTAEI EM, SOHEILIAN M, HERBORT CP, YASERI M: Patterns of uveitis in themiddle East and europe. J Ophthalmic Vis Res 2011; 6: 233-40.
12. SALEH OA, BIRNBAUM AD, TESSLER HH, GOLDSTEIN DA: Behçet uveitis in theAmerican midwest. Ocul Immunol Inflamm 2012; 20: 12-7.
13. YAZICI H, TÜZÜN Y, PAZARLI H et al.: Influence of age of onset and patient's sex on the prevalence and severity of manifestations of Behçet's syndrome. Ann Rheum Dis 1984; 43: 783-9.
14. HAZIROLAN D, SUNGUR G, DUMAN S: Demographic, clinical, and ocular features in patients with late-onset Behçet disease. Ocul Immunol Inflamm 2012; 20: 119-24.
15. JUNG YS, YOON JY, HONG SP, KIM TI, KIM WH, CHEON JH: Influence of age atdiagnosis and sex on clinical course and long-term prognosis of intestinal Behçet's disease. Inflamm Bowel Dis 2012; 18: 1064-71.
16. HAMURYUDAN V, HATEMI G, SUT N, UGURLU S, YURDAKUL S, YAZICI H: Frequent oralulceration during early disease may predict a severe disease course in males with Behçet's syndrome. Clin Exp Rheumatol 2012; 30 (3 Suppl. 72): S32-4.
17. DIRESKENELI H, SARUHAN-DIRESKENELI G: Disease Mechanisms. In YAZICI Y, YAZICI H (Eds.) Behçet's syndrome. New York, Springer; 2010: 243-65.
18. GUL A, OHNO S: HLA-B51 and Behçet disease. Ocul Immunol Inflamm 2012; 20: 37- 43.
19. REMMERS EF, COSAN E, KIRINO Y et al.: Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet's disease. Nat Genet 2010; 42: 698-702.
20. MIZUKI N, MEGURO A, OTA M et al.: Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behçet's disease susceptibility loci. Nat Genet 2010; 42: 703-6.
21. KIRINO Y, BERTSIAS G, ISHIGATSUBO Y et al.: Genome-wide association analysis identifies new susceptibility loci for Behçet's disease and epistasis between HLA-B*51 and ERAP1. Nat Genet 2013; 45: 202-7.
22. HOU S, YANG Z, DU L et al.: Identification of a susceptibilitylocus in STAT4 for Behçet's disease in Han Chinese in a genome-wide association study. Arthritis Rheum 2012; 64: 4104-13.
23. CÉNIT MC, ORTEGO-CENTENO N, RAYA E et al.: Influence of the STAT3 genetic variants in the susceptibility to psoriatic arthritis and Behçet's disease. Hum Immunol 2013; 74: 230-3.
24. KIRINO Y, ZHOU Q, ISHIGATSUBO Y et al.: Targeted resequencing implicates the familial Mediterranean fever gene MEFV and the toll-like receptor 4 gene TLR4 in Behçet disease. Proc Natl Acad Sci USA 2013; 110: 8134-9.
25. HUGHES T, COIT P, ADLER A et al.: Identification of multiple independent susceptibility loci in the HLA region in Behçet's disease. Nat Genet 2013; 45: 319-24.
26. ATZENI F, BOIARDI L, CASALI B et al.: CC chemokine receptor 5 polymorphism in Italian patients with Behçet's disease. Rheumatology (Oxford) 2012; 51: 2141-5.
27. LI H, LIU Q, HOU S et al.: TNFAIP3 gene polymorphisms confer risk for Behçet's disease in a Chinese Han population. Hum Genet 2013; 132: 293-300.
28. YIGIT S, TURAL S, RUSTEMOGLU A et al.: DD genotype of ACE gene I/D polymorphism is associated with Behçet disease in a Turkish population. Mol Biol Rep 2013; 40: 365-8.
29. OGUZ E, ALASEHIRLI B, PEHLIVAN Y et al.: Association between Rho-kinase (ROCK 2) gene polymorphisms and Behçet's disease. Translres 2012; 160: 428-34.
30. ZHENG X, WANG D, HOU S et al.: Association of macrophage migration inhibitory factor gene polymorphisms with Behçet's disease in a Han Chinese population. Opthalmology 2012; 119: 2514-8.
31. HOU S, XIAO X, ZHOU Y et al.: Genetic variant on PDGFRL associated with Behçet's disease in Chinese Han populations. Hum Mutat 2013; 34: 74-8.
32. HOU S, XIAO X, LI F: Two-stage association study in Chinese Han identifies two independent associations in CCR1/CCR3 locus as candidate for Behçet's disease susceptibility. Hum Genet 2012; 131: 1841-50.
33. RUSTEMOGLU A, GÜL Ü, GÜMÜS-AKAY G et al.: MDR1 gene polymorphisms maybe associated with Behçet's disease and its colchicum treatment response. Gene 2012; 505: 333-9.
34. PARLAKGUL G, GUNEY E, ERER B et al.: Expression of regulatory receptors on γδ T Cells and their cytokine production in Behçet's disease. Arthritis Res Ther 2013; 15: R15.
35. TÜRE-ÖZDEMIR F, TULUNAY A, ELBASI MO et al.: Pro-inflammatory cytokine and caspase- 1 responses to pattern recognition receptor activation of neutrophils and dendritic cells in Behçet's disease. Rheumatology (Oxford) 2013; 52: 800-5.
36. YAZICI H, UGURLU S, SEYAHI E: Behçet syndrome: is it one condition? Clin Rev Allergy Immunol 2012; 43: 275-80.
37. CHO SB, ZHENG Z, AHN KJ et al.: Serum IgA reactivity against GroEL of Streptococcus sanguinis and human heterogeneous nuclear ribonucleoprotein A2/B1 in patients with Behçet disease. Br J Dermatol 2013; 168: 977- 83.
38. CHO S, ZHENG Z, CHO SB, CHOI MJ, LEE KH, BANG D: Streptococcus sanguinis and the sera of patients with Behçet's disease stimulate membrane expression of a-enolase in human dermal microvascular endothelial cells. Arch Dermatol Res 2013; 305: 223-32.
39. YOSHIDA A, KAWASHIMA H, MOTOYAMA Y et al.: Comparison of patients with Behçet's disease in the 1980s and 1990s. Ophthalmology 2004; 111: 810-5.
40. TUGAL-TUTKUN I, ONAL S, ALTAN-YAYCIOGLU R et al.: Uveitis in Behçet disease: an analysis of 880 patients. Am J Ophthalmol 2004; 138: 373-80.
41. CINGU AK, ONAL S, URGANCIOGLU M, TUGAL-TUTKUN I: Comparison of presenting features and three-year disease course in Turkish patients with Behçet uveitis who presented in the early 1990s and the early 2000s. Ocul Immunol Inflamm 2012; 20: 423-8.
42. YANG SS, PARK KM, PARK YJ et al.: Peripheral arterial involvement in Behçet's disease: an analysis of the results from a Korean referral center. Rheumatol Int 2013 Feb 16. [Epub ahead of print]
43. TUZUN H, SEYAHI E, ARSLAN C, HAMURYUDAN V, BESIRLI K, YAZICI H: Management and prognosis of nonpulmonary large arterial disease in patients with Behçet disease. J Vasc Surg 2012; 55: 157-63.
44. ZHU YL, WU QJ, GUO LL et al.: The clinical characteristics and outcome of intracardiac thrombus and aortic valvular involvement in Behçet's disease: an analysis of 20 cases. Clin Exp Rheumatol 2012; 30 (Suppl. 72): S40-45.
45. HA YJ, JUNG SY, LEE KH et al.: Long-term clinical outcomes and risk factors for the occurrence of post-operative complications after cardiovascular surgery in patients with Behçet's disease. Clin Exp Rheumatol 2012; 30 (Suppl. 72): S18-26.
46. TALARICO R, D'ASCANIO A, FIGUS M et al.: Behçet's disease: features of neurological involvement in a dedicated centre in Italy. Clin Exp Rheumatol 2012; 30 (Suppl. 72): S69-72.
47. KURAL-SEYAHI E, FRESKO I, SEYAHI N et al.: The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore). 2003; 82: 60- 76.
48. PEÑO IC, De las HERAS REVILLA V, CARBONELL BP et al.: Neuro-Behçet disease: clinical and demographic characteristics. Eur J Neurol 2012; 19: 1224-7.
49. GÜNDÜZ T, EMIR ö, KÜRTÜNCÜ M et al.: Cognitive impairment in neuro-Behçet's disease and multiple sclerosis: a comparative study. Int J Neurosci 2012; 122: 650-6.
50. JUNG YS, CHEON JH, PARK SJ, HONG SP, KIM TI, KIM WH: Clinical course of intestinal Behçet's disease during the first five years. Dig Dis Sci 2013; 58: 496-503.
51. LEE HJ, KIM YN, JANG HW et al.: Correlations between endoscopic and clinical disease activity indices in intestinal Behçet's disease. World J Gastroenterol 2012; 18: 5771-8.
52. LIU S, REN J, XIA Q et al.: Preliminary Casecontrol Study to Evaluate Diagnostic Values of C-Reactive Protein and Erythrocyte Sedimentation Rate in Differentiating Active Crohn's Disease From Intestinal Lymphoma, Intestinal Tuberculosis and Behçet's Syndrome. Am J Med Sci 2013 May 17. [Epub ahead of print].
53. MISAGO N, TADA Y, KOARADA S, NARISAWA Y: Erythema nodosum-like lesions in Behçet's disease: a clinicopathological study of 26 cases. Acta Derm Venereol 2012; 92: 681-6.
54. DEMIRKESEN C, TÜZÜNER N, MAT C et al.: Clinicopathologic evaluation of nodular cutaneous lesions of Behçet syndrome. Am J Clin Pathol 2001; 116: 341-6.
55. CHO SB, KIM J, KANG SW et al.: Renal manifestations in 2007 Korean patients with Behçet's disease. Yonsei Med J 2013; 54: 189- 96.
56. CINAR S, CINAR F, KIRAN S: Is there a need for audiologic evaluation in patients with Behçet disease?. Ear Nose Throat J 2012; 91: E15-9.
57. GURBUZLER L, INANIR A, YELKEN K et al.: Behcet's disease impairs voice quality without laryngeal and hypopharyngeal involvement. Eur Arch Otorhinolaryngol 2012; 269: 2539-42.
58. MELIKOGLU M, MELIKOGLU MA: The prevalence of fibromyalgia in patients with Behçet's disease and its relation with disease activity. Rheumatol Int 2013; 33: 1219-22.
59. YALÇIN B, GÜR G, ARTÜZ F, ALLI N: Prevalence of Metabolic Syndrome in Behçet Disease: A Case-Control Study in Turkey. Am J Clin Dermatol 2013 Jun 13. [Epub ahead of print]
60. Al MOSAWI ZS, MADAN W, FAREED E: Pediatric-onset Behçet disease in Bahrain: report of nine cases and literature review. Arch Iran Med 2012; 15: 485-7.
61. OZDOGAN H: Juvenile Behçet's Syndrome. In YAZICI Y, YAZICI H (Eds.) Behçet's Syndrome 1th edn, pp 205-14. New York: Springer, 2010.
62. NOEL N, WECHSLER B, NIZARD J et al.: Behçet's disease and pregnancy. Arthritis Rheum 2013 Jun 18. [Epub ahead of print]
63. HATEMI G, SEYAHI E, FRESKO I, HAMURYUDAN V: Behçet's syndrome: a critical digest of the recent literature. Clin Exp Rheumatol 2012; 30 (Suppl. 72): S80-9.
64. DALVI SR, YILDIRIM R, YAZICI Y: Behçet's Syndrome. Drugs 2012; 72: 2223-41.
65. TUGAL-TUTKUN I, GUPTA V, CUNNINGHAM ET: Differential Diagnosis of Behçet Uveitis. Ocul Immunol Inflamm 2013 Jun 3. [Epub ahead of print]
66. TUGAL-TUTKUN I: Imaging in the diagnosis and management of Behçet disease. Int Ophthalmol Clin 2012; 52: 183-90.
67. OZEN S, EROGLU FK: Pediatric-onset Behçet disease. Curr Opin Rheumatol 2013. [Epub ahead of print].
68. MORA P, MENOZZI C, ORSONI JG, RUBINO P, RUFFINI L, CARTA A: Neuro-Behçet'sdisease in childhood: a focus on the neuro-ophthalmological features. Orphanet J Rare Dis 2013; 8: 18.
69. ARIDA A, FRAGIADAKI K, GIAVRI E, SFIKAKIS PP: Anti TNF agents for Behçet's disease: Analysis of published data on 369 patients. Semin Arthritis Rheum 2011; 41: 61-70.
70. Al RASHIDI S, Al FAWAZ A, KANGAVE D, ABU El-ASRAR A: Long term clinical outcomes in patients with refractory uveitis associated with Behçet disease treated with infliximab. Ocular Immunol Inflamm 2013 Jun 4 (Epub ahead of print).
71. YOSHIDA A, KABURAKI T, OKINAGA K, TAKAMATO M, KAWASHIMA H, FUJINO Y: Clinical background comparison of patients with and without ocular inflammatory attacks after initiation of infliximab therapy. Jpn J Ophthalmol 2012; 56: 536-43.
72. SAKAI T, WATANABE H, KUROYANAGI K et al.: Health and vision related quality of life in patients receiving infliximab therapy for Behçet uveitis. Br J Ophthalmol 2013; 97: 338-42.
73. LEE JH, CHEON JH, JEON SW et al.: Efficacy of infliximab in intestinal Behçet's disease: A Korean multicenter retrospective study. Inflamm Bowel Dis 2013 May 22 (Epub ahead of print)
74. FURUTA S, CHOW YW, CHAUDRY AN, JAYNE D: Switcing of anti-TNF-a agents in Behçet's disease. Clin Exp Rheumatol 2012; 30 (Suppl. 72): S62-8.
75. CHI W, ZHU X, YANG P et al.: Upregulated IL-23 and IL-17 in Behçet patients with active uveitis. Invest Ophthalmol Vis Sci 2008; 49: 3058-64.
76. DICK AD, TUGAL-TUTKUN I, FOSTER S et al.: Secukinumab in the treatment of noninfectious uveitis: Results of three randomized, controlled clinical trials. Ophthalmology 2013; 120: 777-87.
77. HIRANO T, OHGURO N, HOHKI S et al.: A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Mod Rheumatol 2012; 22: 298-302.
78. URBANIAK P, HASLER P, KRETZSCHMAR S: Refractory neuro-Behçet treated by tocilizumab: a case report. Clin Exp Rheumatol 2012; 30 (Suppl. 72): S73-5.
79. DIAMANTOPOULOS AP, HATEMI G: Lack of efficacy of tocilizumab in mucocutaneous Behçet's syndrome: report of two cases. Rheumatology (Oxford) 2013 Apr 4 (Epub ahead of print).
80. HATEMI G, YAZICI H: Behçet's syndrome and micro-organisms. Best Pract res Clin Rheumatol 2011; 25: 389-406.
81. BAERVELDT EM, KAPPEN JH, THIO HB, van LAAR JAM, van HAGEN PM, PRENS EP: Successful long-term triple disease control by ustekinumab in a patient with Behçet's disease, psoriasis and hidranetissuppurativa. Ann Rheum Dis 2013; 72: 626-7.
82. PEREZ-PAMPIN E, CAMPOS-FRANCO J, BLANCO J, MERA A: Remission induction in a case of refractory Behçet disease with alemtuzumab. J Clin Rheumatol 2013; 19: 101-3.